AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27006728
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg weekly plus methotrexate for 24 weeks, continued for 104 weeks; total exposure 798.1 patient-years.
Trial: 27006728
Drug: Conventional DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional DMARD (hydroxychloroquine or sulfasalazine) plus methotrexate for 24 weeks, followed by treatment modification.
Trial: 27006728
Drug: Etanercept (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (continued or added) in the treatment regimen after week 24.
Trial: 27007958
Drug: Incretin-based drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incretin-based drugs (DPP-4 inhibitors and GLP-1 analogues)
Trial: 27007958
Drug: Oral antidiabetic-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antidiabetic-drug combinations
Trial: 27009059
Drug: Marizomib (MRZ)
RxNorm normalized name: Marizomib
DrugBank: Marizomib (DB11762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marizomib (MRZ) schedule A at 0.7 mg/m(2) infused over 10 minutes, administered to 32 patients.
Trial: 27009059
Drug: Marizomib (MRZ)
RxNorm normalized name: Marizomib
DrugBank: Marizomib (DB11762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marizomib (MRZ) schedule B at 0.5 mg/m(2) infused over 2 hours, administered to 36 patients.
Trial: 27009092
Drug: Adjuvant aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant aromatase inhibitors (AIs)
Trial: 27010542
Drug: Primaquine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (single dose 0.25 mg base/kg)
Trial: 27013512
Drug: Monthly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly follow-up without treatment of asymptomatic mono or mixed P. falciparum infections (24 participants)
Trial: 27015562
Drug: Afatinib (ERBB1/2/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (ERBB1/2/4 inhibitor)
Trial: 27015798
Drug: Early antiretroviral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiretroviral therapy (EART) based on lopinavir/r
Trial: 27018703
Drug: Nitroglycerin Ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin Ointment
Trial: 27019745
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy application
Trial: 27019745
Drug: Mobile-sensing application
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile-sensing application promoting daily activities
Trial: 27020111
Drug: Palliative Radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palliative Radiation Therapy (RT) - 25 Gy in 5 daily intensity modulated RT fractions over 1 week
Trial: 27021379
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow mononuclear cell (ABMNC) therapy
Trial: 27021538
Drug: 0.50% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50% chlorhexidine (CHX) gel applied using individual trays (3DS)
Trial: 27021538
Drug: 0.50% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50% chlorhexidine (CHX) gel
Trial: 27021967
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (mean dose 195.6 ± 154.8 mg/day)
Trial: 27022067
Drug: Apatorsen (OGX-427)
RxNorm normalized name: Apatorsen
DrugBank: Apatorsen (DB06094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatorsen (OGX-427) administered i.v. weekly in 21-day cycles following 3 loading doses and over 5 dose levels (200-1000 mg)
Trial: 27025160
Drug: Vorinostat (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (400 mg/d on days 1-14) plus bortezomib (1.3 mg/m² intravenously on days 1, 4, 8, and 11)
Trial: 27025399
Drug: Rise intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rise intervention (treatment education adherence intervention) consisting of 6-10 individual counseling sessions over 6 months.
Trial: 27025608
Drug: VS-6063 (defactinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS-6063 (defactinib, PF-04554878) 200 mg BID
Trial: 27025608
Drug: VS-6063 (defactinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS-6063 (defactinib, PF-04554878) 400 mg BID (RP2D)
Trial: 27025608
Drug: VS-6063 (defactinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VS-6063 (defactinib, PF-04554878) 200-600 mg BID
Trial: 27026379
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with portal vein thrombosis not treated with anticoagulant therapy
Trial: 27029034
Drug: Sunitinib (50mg)
RxNorm normalized name: sunitinib 50 MG
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib (50mg) therapy for 3 cycles
Trial: 27029034
Drug: Nephrectomy samples
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nephrectomy samples after sunitinib treatment
Trial: 27029228
Drug: Bendamustine (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine (90 mg/m² on days 1 and 2) plus Rituximab (375 mg/m² on day 1), every 4 weeks.
Trial: 27030277
Drug: Intravitreal ziv-aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ziv-aflibercept (1.25 mg/0.05 mL)
Trial: 27030531
Drug: Diets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diets containing dietary pulses (median intake of 132 g/d or ∼1 serving/d)
Trial: 27032057
Drug: Oral LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral LNG
Trial: 27032301
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus neoadjuvant chemotherapy (intravenous fluorouracil 500 mg/m², epirubicin 100 mg/m², cyclophosphamide 500 mg/m², and bevacizumab 15 mg/kg during cycles 1-4; docetaxel 100 mg/m² and bevacizumab during cycles 5-8)
Trial: 27032301
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (without bevacizumab)
Trial: 27033958
Drug: Intravesical administration
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical administration of hyaluronic acid and chondroitin sulfate (HA+CS)
Trial: 27036160
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (3 mg/m² IV on day 1), all-trans retinoic acid (45 mg/m² orally on days 4-6 and 15 mg/m² orally on days 7-28), high-dose cytarabine (3 g/m²/12 h IV on days 1-3), mitoxantrone (12 mg/m² IV on days 2-3)
Trial: 27036160
Drug: Patients responding
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients responding to salvage therapy and undergoing allogeneic hematopoietic cell transplantation
Trial: 27039387
Drug: Ixazomib 3
RxNorm normalized name: ixazomib 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib 3 mg weekly
Trial: 27039387
Drug: Ixazomib 4
RxNorm normalized name: ixazomib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib 4 mg weekly
Trial: 27039387
Drug: Ixazomib 5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib 5.5 mg (maximum tolerated dose)
Trial: 27039986
Drug: Piperacillin-tazobactam 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam 4.5 g TID
Trial: 27039986
Drug: Piperacillin-tazobactam 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam 4.5 g BID
Trial: 27040320
Drug: Pralatrexate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pralatrexate (10 to 30 mg/m²) + Bortezomib (1.3 mg/m²)
Trial: 27042163
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 220 mg once daily (first dose 110 mg 1-4 h after surgery)
Trial: 27042326
Drug: Augmentation index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation index (AIx@HR75) measurement
Trial: 27043883
Drug: Red blood
RxNorm normalized name: Red blood cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red blood cell infusions
Trial: 27043883
Drug: Plasma infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma infusions
Trial: 27044576
Drug: tiotropium+olodaterol 5/5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium+olodaterol 5/5 µg with exercise training
Trial: 27044576
Drug: tiotropium+olodaterol 5/5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium+olodaterol 5/5 µg without exercise training
Trial: 27044576
Drug: tiotropium 5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium 5 µg
Trial: 27044938
Drug: LY2606368 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2606368 at 40 mg/m(2) (schedule 1)
Trial: 27044938
Drug: LY2606368 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2606368 at 105 mg/m(2) (schedule 2)
Trial: 27045164
Drug: Bosutinib therapy
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib therapy in AP CML patients
Trial: 27045164
Drug: Bosutinib therapy
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib therapy in BP CML patients
Trial: 27045862
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance index effect on betatrophin levels
Trial: 27047630
Drug: Micro-focused ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-focused ultrasound with visualization with vertical vectoring treatment
Trial: 27048835
Drug: Probiotic combination
RxNorm normalized name: PROBIOTIC COMBINATION CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic combination of Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis ssp. lactis BB12 (BB12)
Trial: 27048835
Drug: Control chewing
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control chewing tablet
Trial: 27048911
Drug: Lurasidone 40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 40-120 mg once daily
Trial: 27049457
Drug: CUDC-907 once-daily
RxNorm normalized name: PI3K/HDAC inhibitor CUDC-907
DrugBank: Fimepinostat (DB11891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUDC-907 once-daily (MTD 60 mg)
Trial: 27049457
Drug: CUDC-907 twice-weekly
RxNorm normalized name: PI3K/HDAC inhibitor CUDC-907
DrugBank: Fimepinostat (DB11891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUDC-907 twice-weekly (MTD 150 mg)
Trial: 27049457
Drug: CUDC-907 three-times-weekly
RxNorm normalized name: PI3K/HDAC inhibitor CUDC-907
DrugBank: Fimepinostat (DB11891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUDC-907 three-times-weekly (MTD 150 mg)
Trial: 27049457
Drug: CUDC-907 5/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUDC-907 5/2 dosing schedule (MTD 60 mg)
Trial: 27049694
Drug: Women with
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with anaemia (Hb <120 g/l)
Trial: 27052658
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (1000 mg once a day) plus prednisone (5 mg twice a day)
Trial: 27054297
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral glucose tolerance test (OGTT)
Trial: 27055247
Drug: SMT C1100
RxNorm normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT C1100 (50 mg/kg on Days 1 and 11, 50 mg/kg bid on Days 2 to 10)
Trial: 27055247
Drug: SMT C1100
RxNorm normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT C1100 (100 mg/kg on Days 1 and 11, 100 mg/kg bid on Days 2 to 10)
Trial: 27055247
Drug: SMT C1100
RxNorm normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT C1100 (100 mg/kg on Days 1 and 11, 100 mg/kg tid on Days 2 to 10)
Trial: 27055731
Drug: FOLFIRINOX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX plus PF-04136309 (500 mg twice daily)
Trial: 27056586
Drug: Reslizumab 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reslizumab 0.3 mg/kg
Trial: 27057326
Drug: Experimental formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental formula containing L. reuteri, GOS (5.50 g/L), and FOS (0.36 g/L)
Trial: 27057326
Drug: Control formula
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formula containing only L. reuteri
Trial: 27058744
Drug: Intra-articular hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hypertonic dextrose injections (12.5% dextrose, 10 mL, four to six monthly injections)
Trial: 27060341
Drug: Etravirine 5.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 5.2 mg/kg twice daily (maximum 200 mg twice daily) plus background antiretrovirals
Trial: 27063977
Drug: OTX015 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX015 at 80 mg/day (14 days on, 7 days off)
Trial: 27063978
Drug: OTX015 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX015 at 80 mg once a day (14 days on, 7 days off)
Trial: 27063978
Drug: OTX015 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX015 at 120 mg once a day
Trial: 27063978
Drug: OTX015 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX015 at 40 mg twice a day
Trial: 27063978
Drug: OTX015 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX015 at 80 mg once a day
Trial: 27066336
Drug: Evolocumab self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab self-administered biweekly over 6 weeks (n=149)
Trial: 27066336
Drug: Evolocumab self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab self-administered monthly over 12 weeks (n=164)
Trial: 27066336
Drug: Evolocumab self-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab self-administration
Trial: 27066336
Drug: Evolocumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (both dosing schedules and devices)
Trial: 27066464
Drug: Low-dose methylprednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methylprednisolone therapy (MPT)
Trial: 27067321
Drug: Pod-intravaginal ring
RxNorm normalized name: Senna pod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pod-intravaginal ring (pod-IVR) delivering a combination of TDF and MVC
Trial: 27067336
Drug: Sulfamethoxazole-trimethoprim (SXT)
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfamethoxazole-trimethoprim (SXT) administered orally at a dose of 960 mg once daily
Trial: 27068396
Drug: Artesunate-Mefloquine (ASMQ)
RxNorm normalized name: artesunate and mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-Mefloquine (ASMQ) fixed-dose combination
Trial: 27068662
Drug: Recruitment strategies
RxNorm normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment strategies including preparation, process, and patient-centeredness
Trial: 27071063
Drug: Broccoli sprout
RxNorm normalized name: BROCCOLI SPROUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli sprout homogenate (BSH) containing sulforaphane (SFN), dosage and duration not specified.
Trial: 27071399
Drug: Proactive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive care (mailed invitation followed by telephone outreach, offer of smoking cessation services, access to pharmacotherapy)
Trial: 27071922
Drug: Binimetinib 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib 45 mg BID
Trial: 27071922
Drug: Binimetinib 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib 30 mg BID
Trial: 27071922
Drug: Binimetinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib (both doses)
Trial: 27072954
Drug: Transdermal latrepirdine
RxNorm normalized name: Latrepirdine
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal latrepirdine (5 mg and 10 mg for EMs)
Trial: 27072954
Drug: Oral latrepirdine
RxNorm normalized name: Latrepirdine
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral latrepirdine (8.14 mg)
Trial: 27074795
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) abatacept (single dose at baseline) followed by 4 weeks break and then continuation of weekly SC abatacept from day 28.
Trial: 27075016
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of olaparib and irinotecan
Trial: 27075906
Drug: Elevated MMA
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated MMA (>271 nmol/L)
Trial: 27076600
Drug: Aldosterone Antagonist
RxNorm normalized name: Aldosterone antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone Antagonist (AA)
Trial: 27076600
Drug: Renin-Guided Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-Guided Therapy (RGT)
Trial: 27076940
Drug: S-1 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 at 60 mg/m(2)/day
Trial: 27076940
Drug: S-1 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 at 70 mg/m(2)/day
Trial: 27076940
Drug: S-1 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 at 80 mg/m(2)/day
Trial: 27078728
Drug: Sunitinib, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib, a small tyrosine kinase inhibitor
Trial: 27078728
Drug: Bevacizumab, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab, a therapeutic antibody
Trial: 27079334
Drug: Dual-antiplatelet therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-antiplatelet therapy with aspirin and clopidogrel after PCI
Trial: 27080929
Drug: Anakinra (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (recombinant human IL-1 receptor antagonist) administered by daily subcutaneous injection for 2-6 weeks
Trial: 27084282
Drug: Nurse educational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse educational oral feeding programme
Trial: 27084281
Drug: Antirheumatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antirheumatic treatment (biologicals and/or conventional synthetic DMARDs)
Trial: 27084534
Drug: Stage-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage-based treatment approach
Trial: 27084692
Drug: Escitalopram 10-20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10-20 mg/d for 16 weeks, augmented with aripiprazole 2-10 mg/d if clinically warranted after 8 weeks
Trial: 27085172
Drug: bivalent oral
RxNorm normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent oral polio vaccine (bOPV)
Trial: 27087519
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg daily plus pantoprazole 40 mg twice daily for 6 months
Trial: 27088859
Drug: Eplerenone 25
RxNorm normalized name: eplerenone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 25 mg/d for 8 weeks
Trial: 27090116
Drug: PDA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDA with injection reminder function
Trial: 27090116
Drug: PDA without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDA without injection reminder function
Trial: 27090917
Drug: Insulin injection
RxNorm normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin injection at the upper inner thigh